RNA-Seq Blog Transcriptome Research & Industry News
Philadelphia Coalition for a Cure (PC4C), a newly launched cooperative clinical diagnostics and research initiative announced that it will collaborate in a study together with Children’s Hospital of Orange County (CHOC) directed to the study and diagnosis of adult and pediatric brain tumors.
To support the study, CHOC and PC4C members selected NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, to supply participating study researchers with its comprehensive molecular profiling and diagnostics test, GPS Cancer, to better inform treatment strategies for patients with brain tumors and further share these data with the worldwide research community. The PC4C consists of members from the Division of Neurosurgery and Center for Data Driven Discovery at the Children’s Hospital of Philadelphia (CHOP); Hyundai Cancer Institute at the Children’s Hospital of Orange County (CHOC), and the neurosurgical departments of the Perelman School of Medicine at the University of Pennsylvania, the Lewis Katz School of Medicine at Temple University; the Drexel University College of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University and Cooper Medical School of Rowan University.
“Brain tumors can occur at any age, and can be found in anyone. They are the leading cause of disease-related death in children and this year alone more than 20,000 adults will be newly diagnosed with brain tumors” said Dr. Jay Storm, M.D., Chief of the Division of Neurosurgery at The Children’s Hospital of Philadelphia. “Through the PC4C, CHOP, CHOC and the leading adult Philadelphia institutions are coming together to define a new clinical and research collaborative ecosystem that harnesses partnerships among leading academic centers, commercial partners and payers in order do what needs to be done on behalf of patients – identify therapies and accelerate discovery. With the guidance of the GPS Cancer test, neurosurgeons, oncologists and the many others who are making influential decisions are newly empowered because of the level and depth of information that this product brings. Together we’re embarking on an incredibly exciting journey toward revolutionizing cancer care.”
GPS Cancer™ is a unique, molecular scan available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. Cancer Breakthroughs 2020 will continue to work with the PC4C to further its reach toward onboarding key stakeholders in the cancer community to fight and win the war against cancer. The PC4C, in its commitment to testing and vetting leading edge technologies through clinical trials, aligns with the Cancer Breakthroughs 2020 program’s Quantitative Integrative Lifelong Trial (QUILT) which is designed to evaluate novel combinations of immunotherapies with the goal of achieving durable, long-lasting remission for patients with cancer.
Source – PR Newswire
